entertainment -WSS

entertainment

author：focus 2025-10-01 18:23:56 - browse：436

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Alabama IVF ruling threatens families facing fatal genetic disease

WSS

A solution to the after

New documents shed light on MD Anderson Cancer Institute feud

Creating egg and sperm cells from stem cells raises ethical issues

Health AI adoption puts security, privacy startups on investors' radar

A new nitrogen execution bill also undermines medical licensing

Gene editing the human germline: What are the risks?

focus

entertainment

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Leading voice in opioid treatment defends methadone clinic system

Medicare details structure of new drug price negotiation program

Physicians and social media: If you see something, say something?

Anesthesiologist group: stop taking Ozempic before surgery

Community Health Systems hospitals under DOJ investigation

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

App could help diagnose ear infections more accurately — and at home

Virginia high school admissions case could be legal follow

He's a Nobel laureate. Critics say he was misleading on Covid

entertainment

A new nitrogen execution bill also undermines medical licensing

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Health AI adoption puts security, privacy startups on investors' radar

Positive childhood experiences can help future health

The Harvard botanist who searched for psychedelics in the Amazon

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

entertainment

focus

entertainment

hotspot